Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Dermia, Maruho ink license deal
December 2016
SHARING OPTIONS:

MENLO PARK, Calif.—Biopharmaceutical company Dermira Inc. and Maruho Co. Ltd. have struck up an exclusive license agreement under which Dermira has granted Maruho an exclusive license for the development and commercialization of DRM04 in Japan. The product candidate is a topical anticholinergic being developed for the treatment of primary axillary hyperhidrosis (excessive underarm sweating). Per the terms of the agreement, Maruho will make an initial license payment to Dermira of $25 million. Dermira also stands to receive additional payments totaling up to $70 million if certain milestones and sales thresholds are met, as well as royalties of up to a low double-digit percentage of net product sales in Japan. Maruho will fund all development and commercial costs for DRM04 in Japan, and, pending talks with Japanese authorities, intends to launch a Phase 1 clinical trial for DRM04 in Japan.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.